Duloxetine + venlafaxine + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Disorder
Conditions
Anxiety Disorder
Trial Timeline
Apr 1, 2005 → Jan 1, 2007
NCT ID
NCT00122837About Duloxetine + venlafaxine + placebo
Duloxetine + venlafaxine + placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00122837. Target conditions include Anxiety Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00122837 | Phase 3 | Completed |
| NCT00122850 | Phase 3 | Completed |
Competing Products
20 competing products in Anxiety Disorder